Literature DB >> 15023549

Pharmacology of cardiac potassium channels.

Juan Tamargo1, Ricardo Caballero, Ricardo Gómez, Carmen Valenzuela, Eva Delpón.   

Abstract

Cardiac K+ channels are membrane-spanning proteins that allow the passive movement of K+ ions across the cell membrane along its electrochemical gradient. They regulate the resting membrane potential, the frequency of pacemaker cells and the shape and duration of the cardiac action potential. Additionally, they have been recognized as potential targets for the actions of neurotransmitters and hormones and class III antiarrhythmic drugs that prolong the action potential duration (APD) and refractoriness and have been found effective to prevent/suppress cardiac arrhythmias. In the human heart, K+ channels include voltage-gated channels, such as the rapidly activating and inactivating transient outward current (Ito1), the ultrarapid (IKur), rapid (IKr) and slow (IKs) components of the delayed rectifier current and the inward rectifier current (IK1), the ligand-gated channels, including the adenosine triphosphate-sensitive (IKATP) and the acetylcholine-activated (IKAch) currents and the leak channels. Changes in the expression of K+ channels explain the regional variations in the morphology and duration of the cardiac action potential among different cardiac regions and are influenced by heart rate, intracellular signalling pathways, drugs and cardiovascular disorders. A progressive number of cardiac and noncardiac drugs block cardiac K+ channels and can cause a marked prolongation of the action potential duration (i.e. an acquired long QT syndrome, LQTS) and a distinct polymorphic ventricular tachycardia termed torsades de pointes. In addition, mutations in the genes encoding IKr (KCNH2/KCNE2) and IKs (KCNQ1/KCNE1) channels have been identified in some types of the congenital long QT syndrome. This review concentrates on the function, molecular determinants, regulation and, particularly, on the mechanism of action of drugs modulating the K+ channels present in the sarcolemma of human cardiac myocytes that contribute to the different phases of the cardiac action potential under physiological and pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023549     DOI: 10.1016/j.cardiores.2003.12.026

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  118 in total

1.  High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943.

Authors:  Hongwei Cheng; Yihong Zhang; Chunyun Du; Christopher E Dempsey; Jules C Hancox
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Mechanisms underlying the cardiac pacemaker: the role of SK4 calcium-activated potassium channels.

Authors:  David Weisbrod; Shiraz Haron Khun; Hanna Bueno; Asher Peretz; Bernard Attali
Journal:  Acta Pharmacol Sin       Date:  2016-01       Impact factor: 6.150

3.  Retigabine: bending potassium channels to our will.

Authors:  Andre Lagrange
Journal:  Epilepsy Curr       Date:  2005 Sep-Oct       Impact factor: 7.500

4.  H-89 inhibits transient outward and inward rectifier potassium currents in isolated rat ventricular myocytes.

Authors:  Charles Pearman; William Kent; Nicolas Bracken; Munir Hussain
Journal:  Br J Pharmacol       Date:  2006-06-26       Impact factor: 8.739

5.  Pharmacology and surface electrostatics of the K channel outer pore vestibule.

Authors:  Claire C Quinn; Ted Begenisich
Journal:  J Membr Biol       Date:  2007-01-06       Impact factor: 1.843

6.  Abundant expression of KCNE1 in the left ventricle of the miniature pig.

Authors:  Kaori Soma; Kentaro Nagaoka; Masayoshi Kuwahara; Hirokazu Tsubone; Koichi Ito
Journal:  Heart Vessels       Date:  2010-10-27       Impact factor: 2.037

Review 7.  Modification of K+ channel-drug interactions by ancillary subunits.

Authors:  Glenna C L Bett; Randall L Rasmusson
Journal:  J Physiol       Date:  2007-12-20       Impact factor: 5.182

Review 8.  Slow delayed rectifier potassium current (IKs) and the repolarization reserve.

Authors:  Norbert Jost; Julius Gy Papp; András Varró
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-01       Impact factor: 1.468

9.  Inhibition of the K+ conductance and Cole-Moore shift of the oncogenic Kv10.1 channel by amiodarone.

Authors:  C Barriga-Montoya; A Huanosta-Gutiérrez; A Reyes-Vaca; A Hernández-Cruz; A Picones; F Gómez-Lagunas
Journal:  Pflugers Arch       Date:  2017-12-07       Impact factor: 3.657

10.  Treatment Responsiveness in KCNT1-Related Epilepsy.

Authors:  Mark P Fitzgerald; Martina Fiannacca; Douglas M Smith; Tracy S Gertler; Boudewijn Gunning; Steffen Syrbe; Nienke Verbeek; Hannah Stamberger; Sarah Weckhuysen; Berten Ceulemans; An-Sofie Schoonjans; Massimiliano Rossi; Geneviève Demarquay; Gaetan Lesca; Kern Olofsson; D A Koolen; Frauke Hornemann; Stephanie Baulac; Guido Rubboli; Kelly Q Minks; Bohoon Lee; Ingo Helbig; Dennis Dlugos; Rikke S Møller; David Bearden
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.